{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:40:07Z","timestamp":1789011607247,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ejim.2020.03.005","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T01:04:37Z","timestamp":1584061477000},"page":"86-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-345X","authenticated-orcid":false,"given":"Avi","family":"Leader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arina J","family":"ten Cate-Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.M.","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Spectre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Giaccherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-1306","authenticated-orcid":false,"given":"Anna","family":"Gurevich-Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilon","family":"Krashin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry C.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2020.03.005_bib0001","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/09537104.2015.1131814","article-title":"Prediction of bleeding and prophylactic platelet transfusions in cancer patients with thrombocytopenia","volume":"27","author":"Vinholt","year":"2016","journal-title":"Platelets"},{"key":"10.1016\/j.ejim.2020.03.005_bib0002","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.03.005_bib0003","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs Warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.03.005_bib0004","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","author":"Raskob","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.03.005_bib0005","first-page":"171","article-title":"Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus","volume":"17","author":"Napolitano","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.ejim.2020.03.005_bib0006","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.critrevonc.2018.09.014","article-title":"Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps","volume":"132","author":"Leader","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejim.2020.03.005_bib0007","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","article-title":"Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study","volume":"94","author":"Kopolovic","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejim.2020.03.005_bib0008","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1080\/10428194.2017.1306644","article-title":"Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort","volume":"58","author":"Houghton","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejim.2020.03.005_bib0009","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1002\/ajh.24526","article-title":"Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia","volume":"91","author":"Khanal","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2020.03.005_bib0010","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11239-017-1539-4","article-title":"Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes","volume":"44","author":"Samuelson Bannow","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ejim.2020.03.005_bib0011","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1182\/bloodadvances.2017006130","article-title":"Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation","volume":"1","author":"Li","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejim.2020.03.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2020.03.005_bib0013","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3747\/co.22.2587","article-title":"Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment","volume":"22","author":"Easaw","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejim.2020.03.005_bib0014","series-title":"Cancer-Associated venous thromboembolic disease","year":"2018"},{"key":"10.1016\/j.ejim.2020.03.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/trf.14120","article-title":"Antithrombotic therapy and platelet transfusions in hematologic malignancy patients presenting chemotherapy-induced thrombocytopenia: a French survey","author":"Chalayer","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.ejim.2020.03.005_bib0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.thromres.2016.03.011","article-title":"Variability in management of hematologic malignancy patients with venous thromboembolism and chemotherapy-induced thrombocytopenia","volume":"141","author":"Samuelson","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2020.03.005_bib0017","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijchp.2014.12.001","article-title":"Vignette methodologies for studying clinicians\u2019 decision-making: validity, utility, and application in ICD-11 field studies","volume":"15","author":"Evans","year":"2015","journal-title":"Int J Clin Health Psychol"},{"key":"10.1016\/j.ejim.2020.03.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015231","article-title":"Determinants of treatment duration in the prevention of recurrent venous thromboembolism: a protocol for a balanced vignette experiment","volume":"7","author":"Ten Cate","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2020.03.005_bib0019","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0038-1676520","article-title":"Managing anti-platelet therapy in thrombocytopaenic patients with haematological malignancy: a multinational clinical vignette-based experiment","volume":"119","author":"Leader","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2020.03.005_bib0020","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/0962280211427759","article-title":"Extension of the modified Poisson regression model to prospective studies with correlated binary data","volume":"22","author":"Zou","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.ejim.2020.03.005_bib0021","series-title":"Management and outcomes of anti-thrombotic medication use in thrombocytopenia","year":"2019"},{"key":"10.1016\/j.ejim.2020.03.005_bib0022","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.blre.2019.03.005","article-title":"Atrial fibrillation and cancer - an unexplored field in cardiovascular oncology","volume":"35","author":"Chu","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.ejim.2020.03.005_bib0023","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jth.14478","article-title":"Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH","volume":"17","author":"Delluc","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2020.03.005_bib0024","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.03.005_bib0025","article-title":"Anticoagulation management and outcomes in thrombocytopenic cancer patients with atrial fibrillation","author":"Livneh","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ejim.2020.03.005_bib0026","unstructured":"NCT01855698. PENELOPE observational study: prophylaxis and treatment of arterial and venous thromboembolism2019."},{"key":"10.1016\/j.ejim.2020.03.005_bib0027","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.03.005_bib0028","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review","author":"Samuelson Bannow","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ejim.2020.03.005_bib0029","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2020.03.005_bib0030","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.03.005_bib0031","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.03.005_bib0032","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/jth.14007","article-title":"Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the catch study","volume":"16","author":"Kamphuisen","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2020.03.005_bib0033","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520300935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520300935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:31:59Z","timestamp":1760607119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520300935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":33,"alternative-id":["S0953620520300935"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.03.005","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}